It's 8:30 in the morning. Have you taken your GUMMY today-?
GBA Presents: House of Gummy-!
- Thread starter stonedinvestor
- Start date
GBA Short-->YEXT Yext, Inc.- Loses $4.72 critical support! 
$5.04-0.11(-2.14%)4:00 PM 06/10/24
NYSE |$USD |Pre-Market:$4.38-0.66(-13.10%)8:16 AM
$5.04-0.11(-2.14%)4:00 PM 06/10/24
NYSE |$USD |Pre-Market:$4.38-0.66(-13.10%)8:16 AM
YTD DOWN 65%
Support: $5.10----$4.85///
ANVS- More than 10% is short<----!!!!
ANVS Annovis Bio, Inc.@$6.50 <---- BUY BUY BUY!
$6.50 0.33(+5.35%)4:00 PM 06/10/24
NYSE |$USD |Pre-Market:$6.49-0.01(-0.15%)8:37 AM
The catalyst:
Annovis Bio to post late-stage data for Parkinson's drug in June:
Annovis' buntanetap found safe, effective in high-risk Alzheimer's patients » 08:17 ANVS
The insider:
Support: $5.10----$4.85///
ANVS- More than 10% is short<----!!!!
ANVS Annovis Bio, Inc.@$6.50 <---- BUY BUY BUY!
$6.50 0.33(+5.35%)4:00 PM 06/10/24
NYSE |$USD |Pre-Market:$6.49-0.01(-0.15%)8:37 AM
The catalyst:
Annovis Bio to post late-stage data for Parkinson's drug in June:
Annovis' buntanetap found safe, effective in high-risk Alzheimer's patients » 08:17 ANVS
The insider:
Last edited:
What Happens when HOUSE OF GUMMY's Stock Picks are flashed on the jumbotron?
They just cannot get enough! Fans actually holding up our newsletter which is printed in England on good stationary!!!-- They have even given me a nickname-- Bubbles.
hummmmmmmmmmmmmm
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease
Published: Mar 20, 2024
MALVERN, Pa., March 20, 2024 (GLOBE NEWSWIRE) --Annovis Bio, Inc.(NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced successful completion of data cleaning for its phase II/III study of buntanetap in patients with mild to moderate Alzheimer’s disease (AD). Topline efficacy data is expected in April.
"We are excited to share that we now move from data cleaning to organization and statistical evaluation of data for our Alzheimer’s study, which was completed in February. To clean data this fast is truly a tremendous achievement,” said Cheng Fang, Ph.D., Senior Vice President of Annovis. “The team has been working hard to provide trustworthy data, and we look forward to the topline results as we plan to announce it next month.”
The phase II/III AD study was a randomized, double-blind, placebo-controlled trial investigating the efficacy, safety, and tolerability of buntanetap in patients with mild to moderate AD. This was a dose ranging study where patients received either one of three doses of buntanetap - 7.5mg, 15mg, or 30mg - or placebo on top of their standard of care for 12 weeks. Over 700 patients were screened with a total of 353 patients enrolled and 327 patients completed the study.
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease
Published: Mar 20, 2024
MALVERN, Pa., March 20, 2024 (GLOBE NEWSWIRE) --Annovis Bio, Inc.(NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced successful completion of data cleaning for its phase II/III study of buntanetap in patients with mild to moderate Alzheimer’s disease (AD). Topline efficacy data is expected in April.
"We are excited to share that we now move from data cleaning to organization and statistical evaluation of data for our Alzheimer’s study, which was completed in February. To clean data this fast is truly a tremendous achievement,” said Cheng Fang, Ph.D., Senior Vice President of Annovis. “The team has been working hard to provide trustworthy data, and we look forward to the topline results as we plan to announce it next month.”
The phase II/III AD study was a randomized, double-blind, placebo-controlled trial investigating the efficacy, safety, and tolerability of buntanetap in patients with mild to moderate AD. This was a dose ranging study where patients received either one of three doses of buntanetap - 7.5mg, 15mg, or 30mg - or placebo on top of their standard of care for 12 weeks. Over 700 patients were screened with a total of 353 patients enrolled and 327 patients completed the study.
Little fishy the " data cleaning " haven't heard that one before---
Make This a GUMMY not a LT hold:
Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast
Published: Jun 05, 2024
MALVERN, Pa., June 05, 2024 (GLOBE NEWSWIRE) -- via IBN –Annovis, Bio Inc.(NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), today announced that it will host aninvestor webcastto discuss recent developments and future plans for its lead drug candidate, Buntanetap.
Investor Call Details:
Make This a GUMMY not a LT hold:
Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast
Published: Jun 05, 2024
MALVERN, Pa., June 05, 2024 (GLOBE NEWSWIRE) -- via IBN –Annovis, Bio Inc.(NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), today announced that it will host aninvestor webcastto discuss recent developments and future plans for its lead drug candidate, Buntanetap.
Investor Call Details:
- Date and Time:June 11, 2024, 4:30pm ET.<------------ should move up tomorrow.
- Register
Well Apple had it's big AI reveal and pulled the covers off the AI- hype. What a let down.
It's the exact same as when money mangers try and explain the AI to me.... No doubt on various sub levels AI will be great but to the consumer this is just " 5G " re packaged and puked up.
Basically Apple put a version of their Diary events/ up on the screen and said look with AI now not only do you get a warning about a diary event but you get directions!!!
and for that please mark up our market cap 200%.....
AI = Bulshit /////
It's the exact same as when money mangers try and explain the AI to me.... No doubt on various sub levels AI will be great but to the consumer this is just " 5G " re packaged and puked up.
Basically Apple put a version of their Diary events/ up on the screen and said look with AI now not only do you get a warning about a diary event but you get directions!!!
and for that please mark up our market cap 200%.....
AI = Bulshit /////